Starzl Thomas E
Transplantation Institute, University of Pittsburgh Medical Center (UPMC), 7th Floor, South, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.
Immunol Res. 2007;38(1-3):6-41. doi: 10.1007/s12026-007-0001-7.
The first unequivocally successful bone marrow cell transplantation in humans was recorded in 1968 by the University of Minnesota team of Robert A. Good (Gatti et al. Lancet 2: 1366-1369, 1968). This achievement was a direct extension of mouse models of acquired immunologic tolerance that were established 15 years earlier. In contrast, organ (i.e. kidney) transplantation was accomplished precociously in humans (in 1959) before demonstrating its feasibility in any experimental model and in the absence of a defensible immunologic rationale. Due to the striking differences between the outcomes with the two kinds of procedure, the mechanisms of organ engraftment were long thought to differ from the leukocyte chimerism-associated ones of bone marrow transplantation. This and other concepts of alloengraftment and acquired tolerance have changed over time. Current concepts and their clinical implications can be understood and discussed best from the perspective provided by the life and times of Bob Good.
1968年,明尼苏达大学的罗伯特·A·古德团队记录了人类首例明确成功的骨髓细胞移植手术(加蒂等人,《柳叶刀》2: 1366 - 1369, 1968)。这一成就直接源于15年前建立的获得性免疫耐受小鼠模型。相比之下,器官(即肾脏)移植在人类身上早熟完成(1959年),而此前并未在任何实验模型中证明其可行性,也缺乏合理的免疫学理论依据。由于这两种手术的结果存在显著差异,长期以来人们认为器官移植的机制与骨髓移植中与白细胞嵌合相关的机制不同。随着时间的推移,这种以及其他关于同种异体移植和获得性耐受的概念发生了变化。从鲍勃·古德的生平与时代所提供的视角出发,能够最好地理解和讨论当前的概念及其临床意义。